Marksans Pharma Q2FY18 consolidated net profit rises 1286.7% yoy

Nov 13, 2017 12:11 IST India Infoline Research Team

Marksans Pharma Ltd Q2FY18

Consolidated Results Q2FY18: (Rs. in crore)

Q2FY18 YoY (%)
Revenue 273.8 51.8
EBITDA 31.4 441.4
EBITDA Margin (%) 11.5 825
Net Profit (adjusted) 10.4 1,286.7
***EBITDA margin change is bps
View

Accumulate

Reco. Price

50.15

Last updated on

04-Nov-2017



Marksans Pharma Ltd consolidated revenue for the quarter came in at Rs. 273.8 crore, registering 51.8% yoy increase.

EBITDA for the quarter rose by 441.4% yoy to Rs. 31.4 crore with a corresponding margin expansion of 825 bps. EBITDA margin for the quarter stood at 11.5%. This margin expansion was aided by favourable movements in inventories.
 
The PAT for the quarter came in at Rs. 10.4 crore, yoy increase of 1286.7%. 


Technical View:

Marksans Pharma Ltd is currently trading at Rs. 49.10, up by 0.15 points or 0.31% from its previous closing of Rs. 48.95 on the BSE.
The scrip opened at Rs. 49.70 and has touched a high and low of Rs. 50.90 and Rs. 48.40 respectively. So far 1,46,16,073(NSE+BSE) shares were traded on the counter. The stock is currently trading below its 200 DMA.

Related Story

Open Free Demat Account (Rs699)